Articles

Colorectal cancer (CRC) is the third most common cancer worldwide, and the fourth most common cause of death from cancer.^1,2 It is estimated that in 2009, 146,970 men and women will have been diagnosed with cancer of the colon and rectum in the United States, and that 49,920 will have died from the disease.³ From 2002 to 2006 the median age of diagnosis was 71 years.³

Approximately 192,000 men developed prostate cancer in 2009 and 27,000 died from the disease.¹ Prostate cancer is the most frequently diagnosed cancer in North America and the second most common cause of cancer death in men. Although the number of new cases of prostate cancer has increased in the past decade, the absolute number of deaths has slowly declined.¹ As the incidence of prostate cancer increases, controversies continue about the best possible methods for screening, detection, and treatment.

Lung cancer is the leading cause of cancer death in both men and women in the United States.¹ It is estimated that in 2009, 219,440 men and women were diagnosed with lung cancer and 159,390 men and women died from the disease.² From 1975 to 2001, non–small-cell lung cancer (NSCLC) 5-year survival rates have increased from 11.9% to 15.6%. These statistics are independent of sex, race, age, and stage at diagnosis, and make acutely evident that there have been few advances in the treatment of NSCLC. Read More ›

Acute myeloid leukemia (AML) is a heterogeneous disease affec ting approximately 13,000 people in the United States each year.¹ For younger adults (<60 years) standard induction treatment includes 7 days of cytarabine and 3 days of an anthracycline. Adults 60 years and older may also be treated with this regimen or a less intensive approach using outpatient chemotherapy or supportive care. The intensive chemotherapy regimens have been in use since the 1970s, with little improvement in complete re sponse (CR) rate or overall survival (OS). Read More ›

In 2000, before imatinib was marketed, it was estimated that there would be 4400 new diagnoses of chronic myeloid leukemia (CML) and 2300 patients would die as a result of the disease in the United States.¹ In 2009, the number of estimated new cases of CML increased to 5050, but the number of patients who were expected to succumb to the cancer decreased to 470 patients.² The US Food and Drug Administration’s (FDA) approval of imatinib in 2001 was seen as a giant leap toward improving and prolonging the lives of patients diagnosed with CML. Read More ›

One of the most debilitating toxicities related to chemotherapy is peripheral neuropathy. Read More ›

Opioids remain a mainstay of treatment for moderate-tosevere cancer pain. In this interview, Judith A. Paice, PhD, RN, director, Cancer Pain Program, Division of Hematology-Oncology, Northwestern University, Feinberg School of Medicine, Chicago, discusses the issues surrounding the use of opioids for the management of cancer pain and the role of the oncology nurse in assessing pain and addressing patients' fears about use of these agents.

The past 5 years have ushered in a new era in the treatment of kidney cancer, and new medications are giving patients more options than ever before. In addition, the traditional end points in oncology drug development, such as survival and tumor response, are changing when it comes to this tumor type. The goal of therapy now is to improve symptomatic and functional ability in patients with renal cell carcinoma (RCC).

 The University of Louisiana at Lafayette College of Nursing and Allied Health Professions provides a variety of programs at the undergraduate and graduate levels, including one that offers students the opportunity to achieve the bachelor's of science in nursing (BSN) degree and to begin the master's of science in nursing (MSN) program at the same time through the process of articulation. The college, which offers one of the largest undergraduate nursing programs in the country, has been recognized with state and national awards. In this interview, Melinda G. Read More ›

Diastolic blood pressure (dBP) ≥90 mm Hg may identify whether a patient will benefit from therapy with axitinib, a selective inhibitor of vascular endothelial growth factor (VEGF) receptors, a new study suggests.